Acadia Lifts FY26 Guidance as Q3 Revenue Grows 5.1% to $895M
ACHC has more than doubled off its 52-week low of $11.43 on elevated volume (3.1× avg).
Summary
Acadia raised full-year 2026 guidance across the board: Adjusted EBITDA to $615-625 million from $590-615 million, and Adjusted EPS to $1.70-1.80 from $1.45-1.60. Q3 revenue rose 5.1% to $895.3 million on same-facility revenue growth of 5.2%, with Acute inpatient revenue up 11.3% offsetting an 8.2% decline in Specialty. Adjusted EBITDA was $176.4 million versus $173.0 million a year ago, while Adjusted EPS fell to $0.60 from $0.72 on higher taxes and costs, and GAAP EPS came in at 38 cents. Management also flagged roughly $60 million of incremental EBITDA expected in 2027 from the 16 acute facilities opened over the past four years. The quarter included a $13.4 million favorable Florida supplemental payment accrual versus $5.6 million previously guided, which flatters the EBITDA beat. This follows the September 25 8-K on preliminary approval of the $12 million derivative settlement, with a final hearing set for December. Q3 earnings call is November 5 at 9:00 a.m. ET.
At the time of this announcement, ACHC was trading at $32.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $11.43 to $35.83. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.